Schubert & Co’s Pacific Biosciences PACB Stock Holding History

Schubert & Co’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8	Closed	-$93	–	1073
2023 Q1	$93	Buy	+8	New	+$80	﹤0.01%	1602

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Schubert & Co's PACB Position: Q2 2023 in Review

Schubert & Co sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 8 shares — an estimated $93 sold.

Schubert & Co first reported a position in PACB in Q1 2023 and held it in 1 quarter. The position peaked at $93 in Q1 2023. 272 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

Schubert & Co reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 8 Pacific Biosciences shares in Q2 2023, an estimated $93.
Schubert & Co first reported a position in Pacific Biosciences in Q1 2023 and held it in 1 quarter.
Schubert & Co's Pacific Biosciences position peaked at $93 in Q1 2023.
272 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.